Our Facilities

• Protein separation and expression analyses from biological samples by two-dimensional gel electrophoresis.
• Testing product purity, analyses of drugs, food, and nutrients, and compound identification and quantification by HPLC/GC.
• Identification and structural characterization of chemical compounds and various molecular weight species in a sample (qualitative analyses of small molecules) by LC/MS/MS.
• Identification and absolute quantification of drugs and metabolites in samples through fragmentation and quantification by LC/MS/MS.
• Qualitative analysis of proteins and peptides by LC/MS/MS (QTrap 4000).
• Mass spectrometry-based detection of inborn errors affecting metabolism of the urea cycle, amino acids, organic acids, and fatty acid oxidation.

• All standard cell and molecular biology assays and cell cycle analysis.
• Sterile and non-sterile cell sorting at rates of 20,000 cells/second.
• Screening for proteasome inhibitors by automated microscopy and flow cytometry.
• Apoptosis (Live cell assay) using 2D and 3D models with cells engineered with FRET probes in the nucleus, analyzed using high-throughput imagers.
• Assays for autophagy and screening of mTOR pathway inhibitors.
• Antioxidant assay using mammalian cells (NRF2-EGFP stable cell line).
• Screening for HIF inhibitors using HRE-Luc or HRE-mCherry-Luc.
• Gene expression studies using Step One Plus (Invitrogen 96-well format) and ABI 7900HT (96 and 384 well format).
• Next-generation sequencing: Ion Torrent and PGM platforms from Invitrogen, supporting exome sequencing, transcriptome sequencing, microbiome analysis, etc., with in-house computation facilities for analysis.
• Microarray analysis using the Affymetrix platform.
• Molecular (DNA) HLA-A, -B, -C, -DR, and -DQ low and high-resolution typing, pre-transplant STR engraftment screening, post-transplant STR engraftment analyses, PRA (panel reactive antibody) screening, and flow cytometry cross-match.
• Genotypic and phenotypic characterization of adult and pediatric leukemias.
• Advanced multi-drug resistance testing of bacterial infections.

BioNest clients will also have paid access to use RGCB's Animal House Facility which runs in compliance with all regulatory guidelines on animal usage (IAEC/CPCSEA).

• The animal house facility has transgenic and immune deficient animals with in vivo imaging system (IVIS).
• Assays offered include angiogenesis (tumor specific capillary formation assay), tumor stem cells (in vivo assays), tumor model systems for preclinical validation of compounds (human tumor xenografts) in athymic nude or SCID mice, orthotopic human tumor models in nude mice (colon and pancreas), syngeneic mouse tumor models (colon and breast), chemical carcinogenesis models in mice and rats (colon, gastric, breast and lung), toxicity profiling (ADME/PK studies), autoimmune and inflammatory disease models, etc.

• All standard cell and molecular biology assays and cell cycle analysis.
• Sterile and non-sterile cell sorting at rates of 20,000 cells/second.
• Screening for proteasome inhibitors by automated microscopy and flow cytometry.
• Apoptosis (Live cell assay) using 2D and 3D models with cells engineered with FRET probes in the nucleus, analyzed using high-throughput imagers.
• Assays for autophagy and screening of mTOR pathway inhibitors.
• Antioxidant assay using mammalian cells (NRF2-EGFP stable cell line).
• Screening for HIF inhibitors using HRE-Luc or HRE-mCherry-Luc.
• Gene expression studies using Step One Plus (Invitrogen 96-well format) and ABI 7900HT (96 and 384 well format).
• Next-generation sequencing: Ion Torrent and PGM platforms from Invitrogen, supporting exome sequencing, transcriptome sequencing, microbiome analysis, etc., with in-house computation facilities for analysis.
• Microarray analysis using the Affymetrix platform.
• Molecular (DNA) HLA-A, -B, -C, -DR, and -DQ low and high-resolution typing, pre-transplant STR engraftment screening, post-transplant STR engraftment analyses, PRA (panel reactive antibody) screening, and flow cytometry cross-match.
• Genotypic and phenotypic characterization of adult and pediatric leukemias.
• Advanced multi-drug resistance testing of bacterial infections.